



Supplementary Material

Article Title: Trajectories in Cerebral Blood Flow Following Antidepressant Treatment in Late-Life Depression: Support for the Vascular Depression Hypothesis

Author(s): Wenjing Wei, MD; Helmet T. Karim, PhD; Chemin Lin, MD; Akiko Mizuno, PhD; Carmen Andreescu, MD; Jordan F. Karp, MD; Charles F. Reynolds III, MD; and Howard J. Aizenstein, MD, PhD

DOI Number: 10.4088/JCP.18m12106

List of Supplementary Material for the article

1. [Table 1](#) Average Gray Matter CBF and Associations With Change in MADRS, Years Lived With Depression, and Venlafaxine Levels

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Average Gray Matter CBF Variable	Other Variable of Interest	Analysis	Statistics	p value (uncorrected)
Baseline CBF	Baseline MADRS	Spearman	r (45) = -0.11	0.46
Baseline – End CBF	Baseline MADRS	Spearman	r (45) = -0.02	0.88
Baseline CBF	Baseline – End MADRS	Pearson	r (44) = 0.06	0.70
Baseline – Placebo CBF	Baseline – End MADRS	Pearson	r (44) = -0.16	0.31
Baseline – Single Dose CBF	Baseline – End MADRS	Pearson	r (44) = 0.10	0.52
Single Dose – Week Post-treatment CBF	Baseline – End MADRS	Pearson	r (44) = -0.11	0.46
Baseline – End CBF	Baseline – End MADRS	Pearson	r (44) = -0.33	0.03
Baseline CBF	Years lived with depression	Pearson	r (41) = -0.03	0.87
Baseline – End CBF	Years lived with depression	Pearson	r (41) = -0.08	0.57
Baseline – End CBF	Venlafaxine end	Pearson	r (44) = 0.04	0.78

Supplementary Table 1. Average gray matter CBF and associations with change in MADRS, years lived with depression, and venlafaxine levels.